WikiSWOT
  • Home|
  • About Us|
  • How it Works|
  • Free SWOTs|
  • What's a SWOT?|
  • FAQ|
Pharmaceuticals & Biotech >> Pfizer SWOT Analysis:
Strengths
  • Industry leaders
  • Strong sales and marketing infrastructure
  • Revived blockbuster credentials in recent years - Lyrica, Sutent and Chantix/Champix
  • Strong R&D departments
  • R&D innovation with a broad therapeutic coverage
  • Marketing strength in major geographical and therapeutic areas
  • Existing Patent protection for a number of years on key products
 Weaknesses
  • Drought in blockbuster launches between
     1999 and 2004 (masked by M&A activity)
  • Entrenchment in low growth therapy area
     markets such as CV and CNS
  • Very limited penetration of biologics market
  • Discontinuation of products in the latter stages of development
  • Co-marketing agreements can limit Pfizer's global presence
Opportunities
  • Restructuring strategy designed to cut costs and create a leaner company
  • Funding available to facilitate product/company
  • Acquisitions and in-licensing/co- development opportunities
  • Biologic market expansion
  • Decreasing development time through favorable R&D collaborations and internal efforts
  • Emergence of integrated global markets and globalisation for new products
  • Co-marketing agreements with companies wishing to capitalize on Pfizer's marketing
  • Strengths, providing Pfizer with strong products and therefore revenue growth
Threats
  • Considerable exposure to generic competition, focal point of which is Lipitor, due to lose patent exclusivity in 2011
  • Further large scale M&A activity could further decline Pfizer's profitability
  • Increased competition for core products like Viagra as its high cost encourages use of cheaper alternative treatments
  • An increase in the number of safety issues surrounding Viagra
  • Competition from products similar to Pfizer's in R&D that reach the market close to or before Pfizer's products
  • The new economic potential of emergent China, India and competition in diverse regional markets.
  • Economic downturn influencing consumers' purchasing power
  • Negative publicity
     

History: Version 20 (Newest), Version 19, Version 18, Version 17, Version 16, Version 15, Version 14, Version 13, Version 12, Version 11, Version 10, Version 9, Version 8, Version 7, Version 6, Version 5, Version 4, Version 3, Version 2, Version 1 (Oldest)



Go back to the SWOT analysis index, or start a discussion about Pfizer SWOT analysis by adding a comment below WikiSWOT Comments


amy February 22, 2009
does anyone have citations for this info?? thanks!
 
Name
Email (not shared)
Website

Add comment